Monitoring the emergence of resistance with sotrovimab in immunocompromised patients with COVID-19: LUNAR study
In this immunocompromised population infected with SARS-CoV-2 who received early treatment with sotrovimab, most participants (83.5%) experienced substantial viral load reductions by day 28. Treatment-emergent substitutions occurred in the sotrovimab epitope, including substitutions known to reduce susceptibility in vitro. Several treatment-emergent substitutions were associated with viral persistence.
Authors
- Andrew Skingsley (ORCID: https://orcid.org/0000-0003-4826-4585)
- Jill Walker
- Kim Gemzoe (ORCID: https://orcid.org/0000-0002-4651-327X)
- Luz Marina Martin Bernal
- Michael Brown (ORCID: https://orcid.org/0000-0001-7205-8947)
- Myriam Gharbi (ORCID: https://orcid.org/0000-0002-8994-2816)
- Melissa K. Van Dyke (ORCID: https://orcid.org/0000-0001-7246-2093)
- Anna L. Goodman (ORCID: https://orcid.org/0000-0003-0643-9017)
- David M. Lowe (ORCID: https://orcid.org/0000-0001-6102-2375)
- Helen J. Birch (ORCID: https://orcid.org/0000-0002-4924-4810)
- Elizabeth McKie
- Julianne R. Brown (ORCID: https://orcid.org/0000-0002-4681-9586)
- Claire Bethune
- Alicia Aylott
- Ewan Hunter (ORCID: https://orcid.org/0000-0002-1620-7095)
- William T. Jordan (ORCID: https://orcid.org/0000-0002-1768-0853)
- Effrossyni Gkrania‐Klotsas (ORCID: https://orcid.org/0000-0002-0930-8330)
- Laura Buggiotti (ORCID: https://orcid.org/0000-0002-7404-7800)
- Judith Breuer (ORCID: https://orcid.org/0000-0001-8246-0534)
- Iain Gillespie (ORCID: https://orcid.org/0000-0002-2265-9506)
- Jennifer Han (ORCID: https://orcid.org/0000-0003-4744-8067)
- Jonathan Underwood (ORCID: https://orcid.org/0000-0001-6963-2821)
- Charlotte A. Williams (ORCID: https://orcid.org/0000-0002-8586-8444)
- Christopher Green (ORCID: https://orcid.org/0000-0002-1984-4014)
- Rachel Williams (ORCID: https://orcid.org/0000-0001-9069-6416)
- Charles C. Miller
Institutions
- University of London (GB)
- Cardiff and Vale University Health Board (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Age UK (GB)
- Great Ormond Street Hospital for Children NHS Foundation Trust (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- London School of Hygiene & Tropical Medicine (GB)
- MRC Clinical Trials Unit at UCL (GB)
- GlaxoSmithKline (United States) (US)
- Institute of Child Health (IN)
- The London College (GB)
- University Hospitals Plymouth NHS Trust (GB)
- Golden Gate University (US)
- University College London (GB)
Publication Details
- Journal
- Journal of Infection
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1016/j.jinf.2025.106510
- Citations
- 3
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- Bristol-Myers Squibb
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Celltrion Healthcare
- Celltrion
- National Institute for Health and Care Research
- Department of Health and Social Care
- Medical Research Council
- NIHR Cambridge Biomedical Research Centre